Search results for: Mouse Anti-GAPDH(3E12)-Loading Control Monoclonal Antibody
#29052441 2017/10/20 Save this To Up
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.Despite type 2 diabetes (T2D) being recognized as a bihormonal pancreatic disease, current therapies are mainly focusing on insulin, while targeting glucagon has been long dismissed. However, glucagon receptor (GCGr) antagonists are currently investigated in clinical trials. Area covered: Following a brief description of the rationale for antagonizing GCGr in T2D, lessons from GCGr knock-out mice and pharmacological means to antagonize GCGr, a detailed description of the main results obtained with GCGr antagonists in Phase I-II clinical trials is provided. The development of several small molecules has been discontinued, while new ones are currently considered as well as innovative approaches such as monoclonal antibodies or antisense oligonucleotides inhibiting GCGr gene expression. Their potential benefits but also limitations are discussed. Expert Opinion: The proof-of-concept that antagonizing GCGr improves glucose control in T2D has been confirmed in humans. Nevertheless, some adverse events led to stopping the development of some of these GCGr antagonists. New approaches seem to have a better benefit/risk balance, although none has progressed to Phase III clinical trials so far. Pharmacotherapy of T2D is becoming a highly competitive field so that GCGr antagonists should provide clear advantages over numerous existing glucose-lowering medications before eventually reaching clinical practice.
1981 related Products with: Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.anti HSV (II) gB IgG1 (mo Human Insulin-like Growth EMAP-II Inhibitor Z-ASTD- EMAP-II Inhibitor Z-ASTD- EMAP II Inhibitor Z ASTD EMAP II Inhibitor Z ASTD Interferon-a Receptor Typ EIA for Quantitative Dete Mouse Anti-Human Interleu TNFRSF1B - Goat polyclona IKK-ε Kinase Inhibitor I IKK-ε Kinase Inhibitor I
#29045436 2017/10/18 Save this To Up
Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus.Current post-exposure prophylaxis for rabies virus infection has several limitations in terms of supply, cost, safety, and efficacy. Attempts to replace human or equine rabies immune globulins (HRIG or ERIG) have been made by several companies and institutes. We developed potent monoclonal antibodies to neutralize a broad spectrum of rabies viruses by screening hybridomas received from the U.S. Centers for Disease Control and Prevention (CDC). Two kinds of chimeric human antibodies (chimeric #7 and #17) were constructed by cloning the variable regions from selected hybridomas and the constant region of a human antibody. Two antibodies were bound to antigenic site III and I/IV, respectively, and were able to neutralize 51 field isolates of rabies virus that were isolated at different times and places such as Asia, Africa, North America, South America, and Australia. These two antibodies neutralize rabies viruses with high efficacy in an in vivo test using Syrian hamster and mouse models and show low risk for adverse immunogenicity.
1182 related Products with: Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus.Viral antibodies, anti-R Measles Virus Nucleoprote Measles Virus nucleoprote Hepatitis C Virus antibod Feline Leukemia virus ant Feline Leukemia Virus p27 Feline Leukemia Virus gp7 Feline Leukemia Virus gp7 Hepatitis B Virus antibod Hepatitis B Virus antibod Hepatitis C Virus antibod Hepatitis C Virus antibod
#29037956 2017/10/17 Save this To Up
A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab.It has been reported that 90% of the anti-drug antibody (ADA) to Adalimumab in human patients bound to the TNF-binding area, resulted in the annual loss of responses to Adalimumab up to 24%. It is of urgency to develop a cost-effective and easy-to-use ADA diagnostic kit for diagnosis of potential drug-resistance in patients treated with Adalimumab in clinic hospitals to avoid the tremendous economic and human costs to patients and health-care providers. In this study, we reported the generations of mouse monoclonal and monkey polyclonal antibodies against Adalimumab as assay standards and positive quality controls respectively. A Bridging ELISA assay was successfully developed with a limit of detection (LOD) between 22-80ng/ml. The preliminary validation of assay was carried out first with 50 normal human sera, further validated by screening the ADA in 192 serum samples from monkeys treated with or without Adalimumab. Our data showed that the Bridging ELISA kit is very sensitive, highly specific and ready for study in human clinic trials.
1597 related Products with: A simple and cost-effective assay for measuring anti-drug antibody in human patients treated with Adalimumab.Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon Mouse anti-human type I c Rat anti-human type I col Rat anti-human type I col Human monkey anti-chick t Human monkey anti-chick t Human monkey anti-bovine Human monkey anti-bovine Human monkey anti-porcine Human monkey anti-porcine Human monkey anti-human t
#28993502 2017/10/10 Save this To Up
Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.The bone-derived hormone fibroblast growth factor-23 (FGF-23) activates complexes composed of FGF receptors (FGFRs), including FGFR1, and α-Klotho in the kidney distal tubule (DT), leading to increased sodium retention and hypertension. However, the role of FGFR1 in regulating renal processes linked to hypertension is unclear. Here, we investigated the effects of selective FGFR1 loss in the DT. Conditional knockout (cKO) of FGFR1 in the DT (FGFR1(DT-cKO) mice) resulted in left ventricular hypertrophy (LVH) and decreased kidney expression of α-Klotho in association with enhanced BP, decreased expression of angiotensin converting enzyme 2, and increased expression of the Na(+)-K(+)-2Cl(-) cotransporter. Notably, recombinant FGF-23 administration similarly decreased the kidney expression of α-Klotho and induced LVH in mice. Pharmacologic activation of FGFR1 with a monoclonal anti-FGFR1 antibody (R1MAb1) normalized BP and significantly attenuated LVH in the Hyp mouse model of excess FGF-23, but did not induce a response in FGFR1(DT-cKO) mice. The hearts of FGFR1(DT-cKO) mice showed increased expression of the transient receptor potential cation channel, subfamily C, member 6 (TRPC6), consistent with cardiac effects of soluble Klotho deficiency. Moreover, administration of recombinant soluble Klotho lowered BP in the Hyp mice. Thus, FGFR1 in the DT regulates systemic hemodynamic responses opposite to those predicted by the actions of FGF-23. These cardiovascular effects appear to be mediated by paracrine FGF control of kidney FGFR1 and subsequent regulation of soluble Klotho and TRPC6. FGFR1 in the kidney may provide a new molecular target for treating hypertension.
1145 related Products with: Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene.FGF Receptor 1 (Ab 154) A Estrogen Receptor; Clone Estrogen Receptor; Clone Progesterone Receptor (P Progesterone Receptor (P Estrogen Receptor; Clone Progesterone Receptor (P Human Fibroblast Growth F Human Fibroblast Growth F Human Fibroblast Growth F Amplite™ Luciferase Rep Amplite™ Luciferase Rep
#28974499 2017/10/04 Save this To Up
Interleukin 22 Promotes Blood Pressure Elevation and Endothelial Dysfunction in Angiotensin II-Treated Mice.CD4+ T helper (Th) cells, including Th1, Th2, and Th17 cells, play critical roles in angiotensin II-induced hypertension. Th22 cells, a novel subset of Th cells, take part in cardiovascular diseases by producing IL-22 (interleukin 22). This study aimed to investigate whether IL-22 is involved in hypertension.
1342 related Products with: Interleukin 22 Promotes Blood Pressure Elevation and Endothelial Dysfunction in Angiotensin II-Treated Mice.Human Interleukin-22 IL-2 Interleukins Recombinant Interleukins Recombinant Rat monoclonal anti mouse Mouse Interleukin Array Mouse Interleukin Array ELISA Human , Interleukin ELISA Mouse , Interleukin Interleukin-34 IL34 (N-t Interleukin-34 IL34 anti Angiotensin II [Lys0](Hum anti HSV (II) gB IgG1 (mo
#28972477 2017/10/03 Save this To Up
IMMUNOHISTOCHEMICAL ANALYSIS OF APPENDIX CELL WALL INFILTRATE IN ACUTE PHLEGMONOUS APPENDICITIS.The purpse of the study was to analyze the content of the mucous infiltrate of cells of the lamina propria of the appendix using immunohistochemical analysis in patients with acute phlegmonous appendicitis. The research included 21 patients with acute phlegmonous appendicitis. The control group consisted of 15 persons lacking the inflammation of the intraperitoneal cavity. Primary monoclonal (MC) antibodies (AB) of the mouse used in the immunohistochemical (IHC) research included the following: Ki-67, CD3, CD4, CD8, CD20, CD45, CD45R0, and CD68 (DAKO, Denmark), as well as EnVision+ System-HRP (DAB) optical system. The research has shown that acute phlegmonous appendicitis is characterized by statistically reliable increased infiltration (p<0.001) by B-lymphocytes (CD20), memory T-cells (CD45R0), Ki-67+ cells, macrophages (CD68), T-lymphocytes (CD3), T-helper cells (CD4), cytotoxic T-lymphocytes (CD8), and CD45 cells of the lamina propria of the appendix when compared with the control group. Development of acute phlegmonous appendicitis is characterized by enhance infiltration of the lamina propria by B-lymphocytes (CD20), macrophages (CD68), memory T-cells, and high proliferation activity of the mononuclear cells (Ki-67 index).
2125 related Products with: IMMUNOHISTOCHEMICAL ANALYSIS OF APPENDIX CELL WALL INFILTRATE IN ACUTE PHLEGMONOUS APPENDICITIS.anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m anti HCMV gB IgG1 (monocl CELLKINES Natural Human I CELLKINES INTERLEUKIN 2 ( CELLKINES INTERLEUKIN 2 ( Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Macrophage Colony Stimula Macrophage Colony Stimula
#28957334 2017/09/28 Save this To Up
Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein.Hepatitis E virus (HEV) is responsible for hepatitis E, which represents a global public health problem. HEV genotypes 3 and 4 are reported to be zoonotic, and animals are monitored for HEV infection in the interests of public hygiene and food safety. The development of novel diagnostic methods and vaccines for HEV in humans is thus important topics of research. Opening reading frame (ORF) 2 of HEV includes both linear and conformational epitopes and is regarded as the primary candidate for vaccines and diagnostic tests. We investigated the precise location of the HEV epitopes in the ORF2 protein. We prepared four monoclonal antibodies (mAbs) against genotype 4 ORF2 protein and identified two linear epitopes, G438IVIPHD444 and Y457DNQH461, corresponding to two of these mAbs using phage display biopanning technology. Both these epitopes were speculated to be universal to genotypes 1, 2, 3, 4, and avian HEVs. We also used two 12-mer fragments of ORF2 protein including these two epitopes to develop a peptide-based enzyme-linked immunosorbent assay (ELISA) to detect HEV in serum. This assay demonstrated good specificity but low sensitivity compared with the commercial method, indicating that these two epitopes could serve as potential candidate targets for diagnosis. Overall, these results further our understanding of the epitope distribution of HEV ORF2, and provide important information for the development of peptide-based immunodiagnostic tests to detect HEV in serum.
2663 related Products with: Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein.Anti-Infectious Pancreati Anti-Infectious Pancreati Human Epstein-Barr Virus Mouse Epstein-Barr Virus Recombinant Dengue Virus Rabbit Anti-Polyprotein(H Rabbit Anti-TNIP2 ABIN2 T Rat intestinal fatty acid Human anti hepatitis A vi Bovine prolactin-induced Rat Inactive rhomboid pro Human E Antigen of Hepati
#28945244 2017/09/25 Save this To Up
Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.The Zika virus (ZIKV) epidemic has resulted in congenital abnormalities in fetuses and neonates. Although some cross-reactive dengue virus (DENV)-specific antibodies can enhance ZIKV infection in mice, those recognizing the DENV E-dimer epitope (EDE) can neutralize ZIKV infection in cell culture. We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to control ZIKV infection in the brains, testes, placentas, and fetuses of mice. A single dose of the EDE1-B10 antibody given 3 d after ZIKV infection protected against lethality, reduced ZIKV levels in brains and testes, and preserved sperm counts. In pregnant mice, wild-type or engineered LALA variants of EDE1-B10, which cannot engage Fcg receptors, diminished ZIKV burden in maternal and fetal tissues, and protected against fetal demise. Because neutralizing antibodies to EDE have therapeutic potential against ZIKV, in addition to their established inhibitory effects against DENV, it may be possible to develop therapies that control disease caused by both viruses.
2563 related Products with: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.Mouse Anti-Dengue Virus A Mouse Anti-Dengue Virus A Viral antibodies, anti-R Measles Virus Nucleoprote Measles Virus nucleoprote Hepatitis C Virus antibod Feline Leukemia virus ant Feline Leukemia Virus p27 Feline Leukemia Virus gp7 Feline Leukemia Virus gp7 Hepatitis B Virus antibod Hepatitis B Virus antibod
#28937793 2017/09/22 Save this To Up
Investigating the Antiangiogenic, Anti-drug Resistance and Apoptotic Effects of Soy Isoflavone Extract Alone or in Combination with Docetaxel on Murine 4T1 Breast Tumor Model.One major concern in the treatment of cancer patients during chemotherapy is drug resistance. Here we investigated the effects of soy isoflavone extracts alone or in combination with Docetaxel on the drug resistance, angiogenesis, apoptosis, and tumor volume in mouse 4T1 breast tumor model.
2231 related Products with: Investigating the Antiangiogenic, Anti-drug Resistance and Apoptotic Effects of Soy Isoflavone Extract Alone or in Combination with Docetaxel on Murine 4T1 Breast Tumor Model.Multiple organ tumor and Multiple organ tumor tiss FDA Standard Frozen Tissu FDA Standard Frozen Tissu Multiple organ tumor with Multiple organ tumor tiss Multiple organ tumor tiss Goat Anti-Human ORAI1 CRA Multiple organs tumor and Multiple organ cancer tis Breast cancer and matched Breast cancer and matched
#28931754 2017/09/21 Save this To Up
Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target.Antiphospholipid antibodies, present in one-third of lupus patients, increase the risk of thrombosis. We recently reported a key role for neutrophils - neutrophil extracellular traps (NETs), in particular - in the thrombotic events that define antiphospholipid syndrome (APS). To further elucidate the role of neutrophils in APS, we performed a comprehensive transcriptome analysis of neutrophils isolated from patients with primary APS. Moreover, APS-associated venous thrombosis was modeled by treating mice with IgG prepared from APS patients, followed by partial restriction of blood flow through the inferior vena cava. In patients, APS neutrophils demonstrated a proinflammatory signature with overexpression of genes relevant to IFN signaling, cellular defense, and intercellular adhesion. For in vivo studies, we focused on P-selectin glycoprotein ligand-1 (PSGL-1), a key adhesion molecule overexpressed in APS neutrophils. The introduction of APS IgG (as compared with control IgG) markedly potentiated thrombosis in WT mice, but not PSGL-1-KOs. PSGL-1 deficiency was also associated with reduced leukocyte vessel wall adhesion and NET formation. The thrombosis phenotype was restored in PSGL-1-deficient mice by infusion of WT neutrophils, while an anti-PSGL-1 monoclonal antibody inhibited APS IgG-mediated thrombosis in WT mice. PSGL-1 represents a potential therapeutic target in APS.
2491 related Products with: Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target.NDFIP1 (siRNA target site mFGF 21 (siRNA target sit LacZ (siRNA target site) MOUSE ANTI BOVINE ROTAVIR anti SLAM anti CDw150 IgG MOUSE ANTI BORRELIA BURGD ANTI ACTIVATED X FACTOR A Recombinant Human p21 Act Cell Meter™ JC 10 Mitoc Cell Meter™ JC 10 Mitoc Cell Meter™ NIR Mitocho Cell Meter™ NIR Mitocho
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia